News & Videos - ENDOCYTE INC.

Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Endocyte, Inc. In The U.S. District Court For The Southern District Of New York PR Newswire NEW YORK, Nov. 16, 2018 NEW YORK , Nov. 16, 2018 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Southern District of New York , Case No. 1:18-cv-10392-JMF, on behalf of public common shareholders of Endocyte, Inc....

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Endocyte, Inc. - ECYT PR Newswire NEW YORK, Nov. 1, 2018 NEW YORK , Nov. 1, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York City , is investigating the Board of Directors of Endocyte, Inc. ("Endocyte" or the "Company") (NasdaqGS: ECYT) for possible breaches of fiduciary duty related to the...

...

...

NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Trevena, Inc. (NASDAQ:TRVN), Five Prime Therapeutics, Inc. (NASDAQ:FPRX), Endocyte, Inc. (NASDAQ:ECYT), FireEye, Inc. (NASDAQ:FEYE), CSRA Inc. (NYSE:CSRA), and Orchid Island Capital, Inc. (NYSE:ORC), including updated fundamental summaries, consolidated fiscal reporting, and...

NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of FireEye, Inc. (NASDAQ:FEYE), CSRA Inc. (NYSE:CSRA), Concho Resources Inc. (NYSE:CXO), Trevena, Inc. (NASDAQ:TRVN), Five Prime Therapeutics, Inc. (NASDAQ:FPRX), and Endocyte, Inc. (NASDAQ:ECYT), including updated fundamental summaries, consolidated fiscal reporting, and...

NEW YORK, NY / ACCESSWIRE / November 6, 2017 / Endocyte, Inc. (NASDAQ: ECYT ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 6, 2017 at 4:30 PM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/23978 . To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About Investor Network...

NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Endocyte, Inc. (NASDAQ: ECYT ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at 4:30 PM Eastern Time. To listen to the event live - visit https://www.investornetwork.com/company/23978 . Replay Information The replay will be available online at https://www.investornetwork.com/company/23978 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of...

NEW YORK, NY / ACCESSWIRE / May 10, 2017 / Endocyte, Inc. (NASDAQ: ECYT ) will be discussing their earnings results in their Q1 Earnings Call to be held May 10, 2017 at 8:30 AM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/23978 . Replay Information The replay will be available online at https://www.investornetwork.com/company/23978 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of unique...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

WEST LAFAYETTE, Ind., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that data from ongoing phase 1 trials of Endocyte’s SMDC EC1456 will be presented at the IASLC 17 th World Conference on Lung Cancer on Wednesday, Dec. 7, at 2:30 P.M. CET. The conference will be held at the Messe Wien Exhibition & Congress Center in Vienna, Austria....

- Confirmed Maximum Dose for EC1169 and Initiated Expansion Phase in Prostate Cancer Patients - - First Confirmed RECIST Partial Response Observed in EC1169 Dose Escalation Reported at European Society for Medical Oncology (ESMO) in October – - Conference Call Today at 4:30 p.m. EST - WEST LAFAYETTE, Ind., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy,...

WEST LAFAYETTE, Ind., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, Nov. 9th, at 4:30 p.m. EST to discuss its third quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada)...

WEST LAFAYETTE, Ind., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy today announced that the company’s management team will present at the 25 th Annual Credit Suisse Healthcare Conference on Tuesday, Nov. 8, at 2:00 p.m. MST. The conference will be held at The Phoenician in Scottsdale, AZ. A live audio webcast of the Company’s presentation can be...

WEST LAFAYETTE, Ind., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, presented poster updates on its two lead clinical programs at the European Society for Medical Oncology (ESMO) 2016 Congress, being held in Copenhagen, Denmark October 7-11, 2016. “We are pleased that both EC1456 and EC1169 have shown anti-tumor activity during the dose escalation...

WEST LAFAYETTE, Ind., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented at the European Society for Medical Oncology (ESMO), being held in Copenhagen, Denmark, October 7-11, 2016. Presentations are as follows : Abstract #: 731P Title: “Phase 1 Study of the PSMA-Targeted Tubulysin Small-Molecule Drug...